首页> 外文期刊>British Journal of Clinical Pharmacology >Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia.
【24h】

Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia.

机译:acipimox对混合性高脂蛋白血症患者血液流变学和血浆脂蛋白的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

AIMS: Epidemiological data have shown that haemorheological disorders are associated with an increased risk of atherosclerosis. We evaluated the effect of the nicotinic acid derivative acipimox on haemorheological and lipid parameters in 18 patients with mixed hyperlipoproteinaemia using a randomized, double-blind, placebo-controlled, cross-over study protocol. METHODS: Patients (7 women, 11 men, aged 49.3+/-3.0 years) were investigated with acipimox (dose adjusted to weight, 500 or 750 mg daily) compared with placebo treatment each for 12 weeks. Lipid parameters, whole blood viscosity, plasma viscosity, fibrinogen, and red cell aggregation at native and standardized (0.45) haematocrit as well as red cell filterability were measured at baseline, at week 12 (change of therapy), and at week 24. RESULTS: Total cholesterol concentration (8.30+/-0.32 vs 8.72+/-0.36 mmol/l(-1)) and apolipoprotein B (198.5+/-9.9 vs 217+/-9.9 mg dl(-1)) were significantly lower (P<0.05) during acipimox therapy compared with placebo, no significant changes were observed for triglycerides and low-density lipoprotein [LDL] cholesterol. However, total high-density lipoprotein [HDL] cholesterol (1.24+/-0.05 vs 1.10+/-0.05 mmol l(-1), P<0.001) as well as HDL2 and HDL3 cholesterol (P<0.05) were significantly higher during acipimox therapy. The LDL cholesterol to HDL cholesterol ratio significantly improved during acipimox therapy (4.63+/-0.25 vs 5.49+/-0.26, P<0.001). Red cell aggregation at native and standardized haematocrit were the only haemorheological parameters which improved during acipimox therapy in comparison with placebo (shear rate 3 s(-1):10.69+/-0.40 vs 11.50+/-0.44 U, P<0.05, for native red cell aggregation; 10.40+/-0.36 vs 11.28+/-0.39 U, P<0.05, for standardized red cell aggregation). CONCLUSIONS: We conclude, that the cardiovascular risk profile improves during acipimox therapy due to an elevation in HDL cholesterol and its subfractions as well as a decrease in red cell aggregation.
机译:目的:流行病学数据表明,血液流变学疾病与动脉粥样硬化风险增加有关。我们使用随机,双盲,安慰剂对照,交叉研究方案评估了18名混合性高脂蛋白血症患者的烟酸衍生物acipimox对血液流变学和脂质参数的影响。方法:对患者(7名女性,11名男性,年龄49.3 +/- 3.0岁)进行了acipimox(剂量调整至体重,每天500或750 mg)与安慰剂治疗的比较,每次治疗12周。在基线,第12周(治疗改变)和第24周时测量了血脂参数,全血粘度,血浆粘度,纤维蛋白原和天然和标准(0.45)血细胞比容下的红细胞聚集以及红细胞可过滤性。 :总胆固醇浓度(8.30 +/- 0.32 vs.8.72 +/- 0.36 mmol / l(-1))和载脂蛋白B(198.5 +/- 9.9 vs 217 +/- 9.9 mg dl(-1))显着降低(与安慰剂相比,acipimox治疗期间P <0.05),甘油三酸酯和低密度脂蛋白[LDL]胆固醇未见明显变化。但是,总高密度脂蛋白[HDL]胆固醇(1.24 +/- 0.05 vs 1.10 +/- 0.05 mmol l(-1),P <0.001)以及HDL2和HDL3胆固醇(P <0.05)在阿昔莫昔疗法。 Acipimox治疗期间LDL胆固醇与HDL胆固醇的比率显着提高(4.63 +/- 0.25与5.49 +/- 0.26,P <0.001)。与安慰剂相比,在阿昔莫司治疗期间,在天然和标准血细胞比容下的红细胞聚集是唯一改善的血液流变学参数(剪切速率3 s(-1):10.69 +/- 0.40 vs 11.50 +/- 0.44 U,P <0.05,对于天然红细胞聚集; 10.40 +/- 0.36 vs 11.28 +/- 0.39 U,P <0.05,用于标准化红细胞聚集)。结论:我们的结论是,由于HDL胆固醇及其亚组分的升高以及红细胞聚集的减少,在人们接受acipimox治疗期间,心血管风险有所改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号